Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 18/20 | 0.80 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.78 |
| ▸ | NSD2 | O96028 | 1/20 | 0.78 |
| ▸ | NQO1 | P15559 | 2/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13526647 | 0.94 | NQO2 (0.84) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526642 | 0.89 | NQO2 (1.00) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526643 | 0.88 | NQO2 (0.91) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526628 | 0.87 | NQO2 (1.00) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526753 | 0.83 | NQO2 (0.80) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL9385904 | 0.83 | NQO2 (1.00) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| C-1311 SCHEMBL2442405 | 0.83 | NQO2 (1.00) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| C-1311 SCHEMBL31238169 | 0.83 | NQO2 (1.00) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526758 | 0.83 | NQO2 (0.79) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| Hydrochloric Acid SCHEMBL3379560 | 0.82 | NQO2 (0.98) | NQO2SMARCA2NSD2NQO1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | XANTHUS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | XANTHUS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | FLT3, CSF3R, ABL1 | NQO2 616/4885SMARCA2 1943/4885NSD2 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.